Dr John Prendergast has international experience in commercialising pharmaceuticals for global markets, particularly in the USA. He is chair and co-founder of Palatin Technologies (NYSE: PTN), a US biotechnology company; lead director of Heat Biologics (NASDAQ: HTBX); and co-founder/executive chair of Nejo. Dr Prendergast also held previous US biotechnology board positions particularly as lead director of MediciNova (Nasdaq:MNOV) and Osaka Securities Exchange (#4875) and co-founder/lead director of Avigen. Prior to a career in commercialising pharmaceutical technologies, Dr Prendergast was managing director of Paramount Capital Investments and The Castle Group. Dr Prendergast was also a member of the advisory board of the Institute for the Biotechnology of Infectious Diseases (IBID) at the University of Technology Sydney, now called the ithree Institute.
